Liposomes as vehicles for water insoluble platinum-based potential drug

2-(4-(tetrahydro-2H-pyran-2-yloxy)-undecyl)-propane-1,3-diamminedichloroplatinum(II)

Goran N Kaluđerović, Andrea Dietrich, Harish Kommera, Judith Kuntsche, Karsten Mäder, Thomas Mueller, Reinhard Paschke

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Formulation of liposome delivery system loaded with water insoluble 2-(4-(tetrahydro-2H-pyran-2-yloxy)-undecyl)-propane-1,3-diamminedichloroplatinum(II), LipoTHP-C11 was carried out. The particle size distributions were determined by dynamic light scattering and asymmetrical flow field-flow fractionation indicating size of around 120 nm. Stability study showed that LipoTHP-C11 was stable at 4 °C for more than two months. To test suitability of chosen formulation, LipoTHP-C11 was investigated against several tumor cell lines: H12.1, 1411HP, 518A2, A549, HT-29, MCF-7 and SW1736. Furthermore, toxicity against normal fibroblasts was examined. LipoTHP-C11 may be used as an attractive candidate for further assessment in vivo as antitumor agent.
OriginalsprogEngelsk
TidsskriftEuropean Journal of Medicinal Chemistry
Vol/bind54
Sider (fra-til)567-572
ISSN0223-5234
DOI
StatusUdgivet - 2012

Fingeraftryk

Field Flow Fractionation
Dynamic light scattering
Fibroblasts
Fractionation
Platinum
Tumor Cell Line
Particle Size
Liposomes
Particle size analysis
Antineoplastic Agents
Toxicity
Tumors
Flow fields
Cells
Water
Pharmaceutical Preparations
2-(4-(tetrahydro-2H-pyran-2-yloxy)undecyl)propane-1,3-diamminedichloroplatinum(II)

Citer dette

Kaluđerović, Goran N ; Dietrich, Andrea ; Kommera, Harish ; Kuntsche, Judith ; Mäder, Karsten ; Mueller, Thomas ; Paschke, Reinhard. / Liposomes as vehicles for water insoluble platinum-based potential drug : 2-(4-(tetrahydro-2H-pyran-2-yloxy)-undecyl)-propane-1,3-diamminedichloroplatinum(II). I: European Journal of Medicinal Chemistry. 2012 ; Bind 54. s. 567-572.
@article{54368b28d76e43e5a7f464923789e0dc,
title = "Liposomes as vehicles for water insoluble platinum-based potential drug: 2-(4-(tetrahydro-2H-pyran-2-yloxy)-undecyl)-propane-1,3-diamminedichloroplatinum(II)",
abstract = "Formulation of liposome delivery system loaded with water insoluble 2-(4-(tetrahydro-2H-pyran-2-yloxy)-undecyl)-propane-1,3-diamminedichloroplatinum(II), LipoTHP-C11 was carried out. The particle size distributions were determined by dynamic light scattering and asymmetrical flow field-flow fractionation indicating size of around 120 nm. Stability study showed that LipoTHP-C11 was stable at 4 °C for more than two months. To test suitability of chosen formulation, LipoTHP-C11 was investigated against several tumor cell lines: H12.1, 1411HP, 518A2, A549, HT-29, MCF-7 and SW1736. Furthermore, toxicity against normal fibroblasts was examined. LipoTHP-C11 may be used as an attractive candidate for further assessment in vivo as antitumor agent.",
keywords = "Antineoplastic Agents, Cell Line, Tumor, Humans, Inhibitory Concentration 50, Liposomes, Organoplatinum Compounds, Solubility, Water",
author = "Kaluđerović, {Goran N} and Andrea Dietrich and Harish Kommera and Judith Kuntsche and Karsten M{\"a}der and Thomas Mueller and Reinhard Paschke",
note = "Copyright {\circledC} 2012 Elsevier Masson SAS. All rights reserved.",
year = "2012",
doi = "10.1016/j.ejmech.2012.06.004",
language = "English",
volume = "54",
pages = "567--572",
journal = "European Journal of Medicinal Chemistry",
issn = "0223-5234",
publisher = "Elsevier Masson",

}

Liposomes as vehicles for water insoluble platinum-based potential drug : 2-(4-(tetrahydro-2H-pyran-2-yloxy)-undecyl)-propane-1,3-diamminedichloroplatinum(II). / Kaluđerović, Goran N; Dietrich, Andrea; Kommera, Harish; Kuntsche, Judith; Mäder, Karsten; Mueller, Thomas; Paschke, Reinhard.

I: European Journal of Medicinal Chemistry, Bind 54, 2012, s. 567-572.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Liposomes as vehicles for water insoluble platinum-based potential drug

T2 - 2-(4-(tetrahydro-2H-pyran-2-yloxy)-undecyl)-propane-1,3-diamminedichloroplatinum(II)

AU - Kaluđerović, Goran N

AU - Dietrich, Andrea

AU - Kommera, Harish

AU - Kuntsche, Judith

AU - Mäder, Karsten

AU - Mueller, Thomas

AU - Paschke, Reinhard

N1 - Copyright © 2012 Elsevier Masson SAS. All rights reserved.

PY - 2012

Y1 - 2012

N2 - Formulation of liposome delivery system loaded with water insoluble 2-(4-(tetrahydro-2H-pyran-2-yloxy)-undecyl)-propane-1,3-diamminedichloroplatinum(II), LipoTHP-C11 was carried out. The particle size distributions were determined by dynamic light scattering and asymmetrical flow field-flow fractionation indicating size of around 120 nm. Stability study showed that LipoTHP-C11 was stable at 4 °C for more than two months. To test suitability of chosen formulation, LipoTHP-C11 was investigated against several tumor cell lines: H12.1, 1411HP, 518A2, A549, HT-29, MCF-7 and SW1736. Furthermore, toxicity against normal fibroblasts was examined. LipoTHP-C11 may be used as an attractive candidate for further assessment in vivo as antitumor agent.

AB - Formulation of liposome delivery system loaded with water insoluble 2-(4-(tetrahydro-2H-pyran-2-yloxy)-undecyl)-propane-1,3-diamminedichloroplatinum(II), LipoTHP-C11 was carried out. The particle size distributions were determined by dynamic light scattering and asymmetrical flow field-flow fractionation indicating size of around 120 nm. Stability study showed that LipoTHP-C11 was stable at 4 °C for more than two months. To test suitability of chosen formulation, LipoTHP-C11 was investigated against several tumor cell lines: H12.1, 1411HP, 518A2, A549, HT-29, MCF-7 and SW1736. Furthermore, toxicity against normal fibroblasts was examined. LipoTHP-C11 may be used as an attractive candidate for further assessment in vivo as antitumor agent.

KW - Antineoplastic Agents

KW - Cell Line, Tumor

KW - Humans

KW - Inhibitory Concentration 50

KW - Liposomes

KW - Organoplatinum Compounds

KW - Solubility

KW - Water

U2 - 10.1016/j.ejmech.2012.06.004

DO - 10.1016/j.ejmech.2012.06.004

M3 - Journal article

VL - 54

SP - 567

EP - 572

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

SN - 0223-5234

ER -